Topper, Michael J.
Vaz, Michelle
Marrone, Kristen A.
Brahmer, Julie R.
Baylin, Stephen B.
Article History
Accepted: 13 August 2019
First Online: 23 September 2019
Competing interests
: S.B.B. is an inventor of the methylation-specific PCR platform, which is licensed to MDxHealth in agreement with Johns Hopkins University; S.B.B. and Johns Hopkins University are entitled to royalty sales shares. S.B.B. is on the Scientific Advisory Board for Mirati Therapeutics. J.R.B. is on advisory board/consultant for Amgen, BMS (uncompensated), Celgene, Genentech, Janssen Oncology, Lilly, Merck and Syndax. J.R.B. recieves grant research funding from AstraZeneca/MedImmune, BMS and Merck. K.A.M. is a consultant for AstraZeneca. All other authors declare no competing interests.